| Similar Articles |
|---|
 |
The Motley Fool
April 11, 2007
Rich Duprey |
Foolish Forecast: Checking USANA's Credentials The network marketer of nutritional and personal-care products is set to report its first-quarter 2007 financial results. Investors, here is what you can expect to see.   |
The Motley Fool
April 1, 2008
Brian Lawler |
A Bad Prescription From USANA USANA Health Sciences' products help people lose weight, but the company had a loss of its own. |
The Motley Fool
August 10, 2010
David Meier |
Is USANA Health Sciences' Management Up to the Task? It certainly looks like USANA Health Sciences' management has been creating value for its shareholders. |
The Motley Fool
September 7, 2006
Brian Lawler |
Where's the Love for Martek? What could explain a company reporting a 78% increase in quarterly revenues, yet also being the biggest percentage loser of the day on the Nasdaq? Answer: Guidance for the fourth quarter that is well below what analysts were expecting. |
BusinessWeek
December 20, 2004
Gene G. Marcial |
A Ruddy Glow At USANA When USANA Health Sciences fell to the low 20s in April, Jason Schrotberger of Turner Investment Partners snapped up shares -- convinced that demand for its nutritional supplements would ramp up. He was right. |
The Motley Fool
December 16, 2005
Stephen D. Simpson |
NBTY Needs a Supplement No surprise -- this leading nutritional supplement player is heading toward a cyclical trough. This is probably a stock best left to risk-tolerant types. |
The Motley Fool
June 7, 2005
Stephen D. Simpson |
NBTY Buys a Pipsqueak The supplement giant makes a small but strategic acquisition of Wyeth's vitamin business. Opportunistic investors might want to bone up on NBTY. |
Financial Advisor
July 6, 2010 |
Innovative Alternative Strategies Conference Supplement 2010 The supplement to the Innovative Alternative Strategies Conference is attached. |
The Motley Fool
September 22, 2006
Brian Lawler |
The Truth About Dietary Supplements The real issue here is not about one possibly corrupt supplement company -- it's about customers not knowing that the U.S. supplement industry isn't regulated the way pharmaceutical companies are. |
The Motley Fool
August 22, 2007
Tim Beyers |
Who's Buying Now? Sometimes insiders are buying for all the right reasons. Who's at it this week? Enterprise Products Partners... Lazard Ltd... Meruelo Maddux Properties... etc. |
The Motley Fool
December 12, 2008
Brian Orelli |
Martek Meanders Through the Year Even though growth seems to be slowing down, Infant-supplement maker Martek Biosciences is in a pretty good position. |
The Motley Fool
September 5, 2008
Brian Orelli |
The Right Formula in Any Economy Babies have to eat, so nutritional supplement maker Martek Biosciences is still thriving. |
The Motley Fool
October 25, 2011
Rebecca Lipman |
Q3 Earnings: Here Are the Stocks to Watch on Tuesday Short-sellers seem to think there's upside surprises that might be priced into these names -- do you agree? |
The Motley Fool
February 25, 2008
Brian Lawler |
Supplements Take a Hit The leaders of the company which produces the supplement Enzyte are convicted of deceptive advertising. It was allowed to do this because the FDA takes the opposite approach to supplement producers that it does for pharmaceutical drugmakers. |
